CorMedix Inc. Common Stock CRMD
i
Market dataready · fetched 2026-11-06T13:54:56.094Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T13:45:23.209529442Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-06T13:54:55.659128+00:00
CorMedix Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 5.09 | 102.3% | 9.7% | |||
| 45Δ | 5.55 | 121.1% | 13.6% | 5.21 | 99.8% | 8.6% |
| 50Δ | 5.40 | 124.9% | 12.1% | 5.34 | 97.2% | 7.6% |
| 55Δ | 5.24 | 128.7% | 10.5% | 5.46 | 94.7% | 6.5% |
| 60Δ | 5.08 | 132.5% | 8.9% | 5.59 | 92.1% | 5.4% |
| 65Δ | 5.71 | 89.5% | 4.4% | |||
| 70Δ | 5.84 | 87.0% | 3.3% | |||
| 75Δ | 5.96 | 84.4% | 2.2% | |||
| 80Δ | 3.73 | 325.7% | 10.0% | 6.39 | 99.1% | 1.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.09
- IV
- 102.3%
- B/E move
- 9.7%
45Δ
- Pseudo strike
- 5.55
- IV
- 121.1%
- B/E move
- 13.6%
- Pseudo strike
- 5.21
- IV
- 99.8%
- B/E move
- 8.6%
50Δ
- Pseudo strike
- 5.40
- IV
- 124.9%
- B/E move
- 12.1%
- Pseudo strike
- 5.34
- IV
- 97.2%
- B/E move
- 7.6%
55Δ
- Pseudo strike
- 5.24
- IV
- 128.7%
- B/E move
- 10.5%
- Pseudo strike
- 5.46
- IV
- 94.7%
- B/E move
- 6.5%
60Δ
- Pseudo strike
- 5.08
- IV
- 132.5%
- B/E move
- 8.9%
- Pseudo strike
- 5.59
- IV
- 92.1%
- B/E move
- 5.4%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.71
- IV
- 89.5%
- B/E move
- 4.4%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.84
- IV
- 87.0%
- B/E move
- 3.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.96
- IV
- 84.4%
- B/E move
- 2.2%
80Δ
- Pseudo strike
- 3.73
- IV
- 325.7%
- B/E move
- 10.0%
- Pseudo strike
- 6.39
- IV
- 99.1%
- B/E move
- 1.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 78.21% | |
| 73.72% | |
| 81.15% | |
| 119.67% | |
| 53.76% | |
| 49.64% | |
| 51.91% | |
| 79.72% | |
| 59.69% | |
| 65.23% | |
| 60.91% | |
| 78.83% | |
| 120.67% | |
| 68.73% | |
| 52.75% | |
| 56.08% | |
| 59.65% | |
| 53.90% | |
| 51.49% | |
| 58.77% | |
| 56.69% | |
| 74.87% | |
| 76.02% | |
| 89.77% | |
| 117.20% | |
| 77.36% | |
| 74.51% | |
| 68.67% | |
| 63.14% | |
| 72.15% | |
| 78.07% | |
| 80.06% | |
| 80.38% | |
| 77.26% | |
| 75.50% | |
| 87.02% |
Biotechnology
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug,…
More →CRVS
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is…
More →CTMX
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
More →CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation,…
More →CYTK
Description unavailable
More →DBVT
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered…
More →